Latest Articles
Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab - Physician's Weekly
Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab Physician's Weekly
Published: Feb. 4, 2025, 11:09 a.m.
Judge Indicates 40 Hair Relaxer Lawsuits Over Uterine Cancer, Endometrial Cancer and Ovarian Cancer Will Be Selected for Early Trial Program - AboutLawsuits.com
Judge Indicates 40 Hair Relaxer Lawsuits Over Uterine Cancer, Endometrial Cancer and Ovarian Cancer Will Be Selected for Early Trial Program AboutLawsuits.com
Published: Feb. 3, 2025, 9:15 p.m.
Endometrial Cancer and Mental Health: Challenges and Finding Support - Healthline
Endometrial Cancer and Mental Health: Challenges and Finding Support Healthline
Published: Feb. 3, 2025, 5:51 p.m.
(PDF) Radiotherapy improves stress urinary incontinence but impairs pelvic floor function in endometrial cancer patients: a prospective cohort study - ResearchGate
(PDF) Radiotherapy improves stress urinary incontinence but impairs pelvic floor function in endometrial cancer patients: a prospective cohort study ResearchGate
Published: Feb. 2, 2025, 4:08 a.m.
Retrospective Data Highlight FRα and B7-H4 As Potential ADC Targets in Endometrial Cancer - OncLive
Retrospective Data Highlight FRα and B7-H4 As Potential ADC Targets in Endometrial Cancer OncLive
Published: Feb. 1, 2025, 12:11 a.m.
Retrospective Data Highlight FRα and B7-H4 as Potential ADC Targets in Endometrial Cancer - OncLive
Retrospective Data Highlight FRα and B7-H4 as Potential ADC Targets in Endometrial Cancer OncLive
Published: Feb. 1, 2025, 12:11 a.m.
PPP2R1A Mutations Associated With Prolonged OS in High-Risk Endometrial Cancer - OncLive
PPP2R1A Mutations Associated With Prolonged OS in High-Risk Endometrial Cancer OncLive
Published: Jan. 31, 2025, 8:48 p.m.
New endometrial cancer study highlights overlooked risk factors - Brunel University News
New endometrial cancer study highlights overlooked risk factors Brunel University News
Published: Jan. 31, 2025, 3:25 p.m.
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer - OncLive
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer OncLive
Published: Jan. 30, 2025, 10:54 p.m.
Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer - OncLive
Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer OncLive
Published: Jan. 30, 2025, 10:29 p.m.
Link copied to clipboard!